[go: up one dir, main page]

NO975580L - Fremgangsmåte for å inhibere melanom - Google Patents

Fremgangsmåte for å inhibere melanom

Info

Publication number
NO975580L
NO975580L NO975580A NO975580A NO975580L NO 975580 L NO975580 L NO 975580L NO 975580 A NO975580 A NO 975580A NO 975580 A NO975580 A NO 975580A NO 975580 L NO975580 L NO 975580L
Authority
NO
Norway
Prior art keywords
inhibiting
melanoma
inhibiting melanoma
hexamethyleneamino
piperidino
Prior art date
Application number
NO975580A
Other languages
English (en)
Other versions
NO975580D0 (no
Inventor
Robert A Swift
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO975580L publication Critical patent/NO975580L/no
Publication of NO975580D0 publication Critical patent/NO975580D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet en fremgangsmåte for å inhibere melanomer innbefattende administrering til et menneske som har behov for dette av en effektiv mengde av en forbindelse som har formel (I) hvor R l og R.3 uavhengig av hverandre er hydrogen, -CH3, (a), eller (b), hvor Ar er eventuelt substituert fenyl; R.2 er valgt fra gruppen bestående av pyrrolidin, heksametylenamino og piperidino; eller et farmasøytisk akseptabelt salt eller solvat derav, alene eller i kombinasjon med ett eller flere melanominhiberende midler.
NO975580A 1995-06-06 1997-12-03 Fremgangsmåte for å inhibere melanom NO975580D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/466,673 US5843974A (en) 1995-06-06 1995-06-06 Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
PCT/US1996/009839 WO1996039135A1 (en) 1995-06-06 1996-06-06 Methods of inhibiting melanoma

Publications (2)

Publication Number Publication Date
NO975580L true NO975580L (no) 1997-12-03
NO975580D0 NO975580D0 (no) 1997-12-03

Family

ID=23852667

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975580A NO975580D0 (no) 1995-06-06 1997-12-03 Fremgangsmåte for å inhibere melanom

Country Status (16)

Country Link
US (1) US5843974A (no)
EP (1) EP0747053A3 (no)
JP (1) JPH11507371A (no)
KR (1) KR19990022364A (no)
CN (1) CN1192141A (no)
AU (1) AU702716B2 (no)
CA (1) CA2223157A1 (no)
CZ (1) CZ383197A3 (no)
EA (1) EA000680B1 (no)
HU (1) HUP9901093A3 (no)
IL (1) IL118574A0 (no)
MX (1) MX9709466A (no)
NO (1) NO975580D0 (no)
PL (1) PL323924A1 (no)
WO (1) WO1996039135A1 (no)
ZA (1) ZA964682B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048847A (en) * 1997-09-30 2000-04-11 Dabur Research Foundation Use of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this
US6228850B1 (en) * 1997-09-30 2001-05-08 Dabur Research Foundation Antiangiogenic activity of betulinic acid and its derivatives
US6670345B1 (en) 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
CA2558667A1 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Antisense oligonucleotides for inhibiting the formation of metastases in cancer
JP2007530453A (ja) * 2004-03-19 2007-11-01 ザ　ペン　ステート　リサーチ　ファウンデーション 黒色腫を治療するためのコンビナトリアル法および組成物
CN104780976B (zh) * 2012-08-13 2019-01-01 洛克菲勒大学 治疗和诊断黑素瘤
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
RS65646B1 (sr) 2019-12-13 2024-07-31 Inspirna Inc Soli metala i njihove upotrebe

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
CN1058390C (zh) * 1993-10-15 2000-11-15 伊莱利利公司 苯并噻吩类化合物的用途
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
JPH07149638A (ja) * 1993-10-15 1995-06-13 Eli Lilly & Co 耐性新生物の治療法
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents

Also Published As

Publication number Publication date
KR19990022364A (ko) 1999-03-25
US5843974A (en) 1998-12-01
CN1192141A (zh) 1998-09-02
AU6109096A (en) 1996-12-24
JPH11507371A (ja) 1999-06-29
PL323924A1 (en) 1998-04-27
ZA964682B (en) 1997-12-05
EP0747053A3 (en) 1997-01-29
EP0747053A2 (en) 1996-12-11
CA2223157A1 (en) 1996-12-12
NO975580D0 (no) 1997-12-03
AU702716B2 (en) 1999-03-04
CZ383197A3 (cs) 1998-07-15
EA199800015A1 (ru) 1998-06-25
EA000680B1 (ru) 2000-02-28
HUP9901093A3 (en) 2000-02-28
MX9709466A (es) 1998-02-28
IL118574A0 (en) 1996-10-16
WO1996039135A1 (en) 1996-12-12
HUP9901093A2 (hu) 1999-10-28

Similar Documents

Publication Publication Date Title
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
UA26930C2 (uk) Засіб для іhгібуваhhя еhдометріозу
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO944930D0 (no) Hemming av dysfunksjonell uterin blödning
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO944917D0 (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser
NO970783L (no) Fremgangsmåte for å hindre endometrialkreft
MX9701333A (es) Metodos para inhibir el daño neuronal.
NO20000750L (no) FremgangsmÕte for Õ redusere blodplatetall
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
NO944910L (no) Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
NO983452L (no) FremgangsmÕter for Õ hemme muskuloaponeurotisk fibromatose (desmoide tumorer)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application